Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 31, 2018 08:30 ET | Source: Zynerba Pharmaceuticals, Inc.

Zynerba Pharmaceuticals to Present at the H.C. Wainwright 20th Annual Global Investment Conference

DEVON, Pa., Aug. 31, 2018 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare...
August 02, 2018 06:50 ET | Source: Zynerba Pharmaceuticals, Inc.

Zynerba Pharmaceuticals Reports Second Quarter 2018 Financial Results and Operational Highlights

DEVON, Pa., Aug. 02, 2018 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare...
August 01, 2018 08:46 ET | Source: Zynerba Pharmaceuticals, Inc.

Zynerba Pharmaceuticals to Present at the 38th Annual Canaccord Genuity Growth Conference

DEVON, Pa., Aug. 01, 2018 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare...
July 31, 2018 07:30 ET | Source: Zynerba Pharmaceuticals, Inc.

Zynerba Pharmaceuticals to Host Conference Call to Provide Second Quarter 2018 Business Update

DEVON, Pa., July 31, 2018 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare...
July 20, 2018 09:10 ET | Source: Zynerba Pharmaceuticals, Inc.

Zynerba Pharmaceuticals Announces Pricing of Public Offering of Common Stock

DEVON, Pa., July 20, 2018 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) today announced the pricing of an underwritten public offering of 4,062,500 shares of its common stock at a...
July 19, 2018 16:01 ET | Source: Zynerba Pharmaceuticals, Inc.

Zynerba Pharmaceuticals Announces Proposed Public Offering of Common Stock

DEVON, Pa., July 19, 2018 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) today announced that it intends to offer and sell, subject to market conditions, shares of its common stock...
July 12, 2018 07:30 ET | Source: Zynerba Pharmaceuticals, Inc.

Zynerba Pharmaceuticals Announces New FAB-C Phase 2 Open-Label Data in Patients with Fragile X Syndrome

- Significant Improvements in Behavioral Symptoms Observed in Patients and Sustained through 38 Weeks of Treatment with ZYN002 -- Presentation Today at the 16th NFXF International Fragile X Conference...
July 09, 2018 06:55 ET | Source: Zynerba Pharmaceuticals, Inc.

Zynerba Pharmaceuticals Initiates CONNECT-FX, a Pivotal Clinical Trial of ZYN002 in Fragile X Syndrome

Study will Evaluate the Efficacy and Safety of Transdermally-Delivered Cannabidiol (CBD) in Children and Adolescents with Fragile X Syndrome Top Line Results Expected in Second Half of 2019 Zynerba...
July 05, 2018 07:30 ET | Source: Zynerba Pharmaceuticals, Inc.

Zynerba Pharmaceuticals Announces Top Line Results from ZYN001 THC-Prodrug Patch Phase 1 Study

DEVON, Pa., July 05, 2018 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare...
May 31, 2018 08:00 ET | Source: Zynerba Pharmaceuticals, Inc.

Zynerba Pharmaceuticals to Present at the Jefferies 2018 Global Healthcare Conference

DEVON, Pa., May 31, 2018 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty neuropsychiatric pharmaceutical company dedicated to developing and...